Overview

Defend Against Infections with Precision Pharmacogenomics

Optimize antimicrobial therapies, reduce resistance, and streamline patient outcomes across your health system.
Overview
Infectious diseases require agile and targeted treatments to combat bacterial, viral, fungal, and parasitic pathogens—especially given rising drug resistance. PGxAI's Infectious Diseases module (PGxAegis™) integrates advanced pharmacogenomics with real-world clinical data to guide optimal drug selection and dosing for conditions ranging from common bacterial infections to complex multidrug-resistant strains. By aligning each patient's genetic profile with antimicrobial regimens, PGxAegis™ helps clinicians minimize side effects, reduce hospital stays, and improve patient recovery rates.
100+ essential antimicrobial drugs covered, including antibiotics, antivirals, antifungals, and antimalarials.
60 key genetic markers analyzed for drug metabolism, resistance profiles, and infection severity.
AI-driven insights updated in real time to adapt to evolving pathogens and patient-specific factors.
Key Highlights
Serving every stakeholder in healthcare
1
icon
Broad-Spectrum Coverage
From beta-lactams to antiviral therapies like Oseltamivir, PGxAegis™ provides actionable insights across the infectious disease spectrum.
2
icon
Resistance Mitigation
Genetic data helps identify potential drug resistance, guiding clinicians toward more effective, targeted therapies and prudent antibiotic stewardship.
3
icon
Rapid Response
Real-time AI alerts ensure clinicians can adjust treatments quickly, reducing the risk of complications and improving outcomes.
4
icon
Reimbursable Solutions
Built around recognized CPT codes, facilitating cost-effective and clinically validated infectious disease management.
Clinical Impact
Maximize Clinical Impact with PGXAI
Lower Adverse Events
Tailored regimens help reduce allergic reactions, toxicity, and drug interactions.
Improved Antibiotic Stewardship
Optimized prescribing curbs the overuse of broad-spectrum agents, aiding in the global fight against antimicrobial resistance.
Faster Recovery
Accurate drug selection from the start leads to quicker symptom resolution and shorter hospital stays.
Enhanced Quality Metrics
Reduced readmissions and complications align with value-based care initiatives, potentially boosting reimbursement rates.
Drug Categories
PGxAI supports a broad range of infectious disease therapies
icon
Antibiotics:
Penicillins, Cephalosporins, Fluoroquinolones, Macrolides
Antivirals:
Oseltamivir, Acyclovir, Abacavir, Ribavirin
Antifungals:
Fluconazole, Voriconazole, Posaconazole
Antimalarials:
Chloroquine, Artemether, Primaquine
Immunomodulators:
Interferons for viral infections. Each recommendation is powered by a robust AI engine that factors in genetic variants (e.g., CYP2C19, CYP3A4), pathogen profiles, and clinical guidelines.
Case Study
Summit Infectious Disease Center
icon
Challenge
Rising rates of treatment failure and antibiotic resistance in hospitalized pneumonia cases.
icon
Results
30% reduction in treatment failures over 9 months, improved resistance management, and faster patient recovery times.
What's next
Ready to Shape the Future of Precision Medicine?
Empower your infectious disease teams with AI-driven pharmacogenomics that curb resistance, lower adverse events, and optimize patient recoveries.
Request a Demo
See how PGxAegis™ enhances infectious disease workflows.
arrow icon